A Study of SNIPR001 in People With Blood Cancer Who Are Receiving a Stem Cell Transplant

Full Title

A Phase 1b 2a, Randomized, Double-blind Study to Investigate Safety, Tolerability, PK, PD, and Preliminary Efficacy of Oral Administration of SNIPR001 in Patients with Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplantation Receiving Fluoroquinolone Prophylaxis and Harboring Fluoroquinolone-Resistant Escherichia coli Pre-Transplant

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Ying Taur’s office at 212-639-8849.

Protocol
26-280
Phase
Phase I/II (phases 1 and 2 combined)
Investigator
Ying Taur
Co-Investigators
Melvili Cintron
Diseases
Hematology
Hematology › Hematologic Malignancies
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT06938867
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description